Skip to content

SCOPE Summit 2025: Fast Forward to 2035: What Success Could Look Like in Converging Clinical Research and Care—And How to Get There

This year’s SCOPE conference in Orlando kicked off with a keynote address from Janice Chang, CEO, TransCelerate Biopharma, and Mark McClellan, MD, PhD, director, Duke-Margolis Institute for Health Policy, Former Commissioner, FDA. Titled “Fast Forward to 2035: What Success Could Look Like in Converging Clinical Research and Care—And How to Get There”, the duo discussed how the progress of clinical convergence has been driven by digital advancements, artificial intelligence (AI), and evolving regulatory frameworks.

Read the full article from Applied Clinical Trials here.

Related Blog Posts

The Clinical Trial Enterprise: Can AI Fix It?

Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle.  Read the full article by Rob DiCicco from Drug Discovery News here.

Redesigning Clinical Trials Using Artificial Intelligence

While tech evangelists often tout artificial intelligence (AI) as healthcare’s silver bullet, the reality in clinical trials is more complex. Adoption has been cautious, shaped as much by concerns around trust and governance as by technical hurdles. Still, beneath the surface, methodical innovation is gaining momentum. AI is beginning to reshape how trials are designed,…

How Pandemic-Era Ingenuity Fuels the Future of Clinical Trials

It’s hard to believe that just five years ago, the clinical research industry found itself scrambling to adapt overnight. The COVID-19 pandemic ground global health systems to a halt and forced us all to move faster and more collaboratively than ever before. Read the full article by Allison Cuff Shimooka from The Medicine Maker here.